Accessibility Menu
Spectral Medical logo

Spectral Medical(OTC) EDTXF

Market Cap$290.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-84%
5 Year+220%
1 Year+62%
1 Month+7%
$0.99
-0.60%
-0.01Today
Spectral Medical last closing stock price
MetricPriceDate
Last closeUSD 0.992026-07-31
Spectral Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.33%USD 0.982026-07-24
1 month+7.3%USD 0.922026-07-01
3 month-0.35%USD 0.992026-05-01
Year to date-4.9%USD 1.042025-12-31
1 year+62.13%USD 0.612025-07-31
3 year+312.08%USD 0.242023-08-01
5 year+220.06%USD 0.312021-07-29
Since inception-83.52%USD 6.001992-07-16

Spectral Medical Financials at a Glance

Market Cap

$290.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$2.76M

Net Income (TTM)

-CA$38.03M

EPS (TTM)

-$0.10

P/E Ratio

-10.31

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$0.99

Volume

2,200

Open

$0.99

Previous Close

$0.99

Daily Range

$0.99 - $0.99

52-Week Range

$0.59 - $1.31

Estimated Earnings Date

Aug 7, 2026

EDTXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spectral Medical

Spectral Medical Inc. is a healthcare company focused on developing and commercializing innovative products for the treatment of septic shock. The company operates internationally, offering diagnostic and therapeutic solutions aimed at improving patient outcomes in critical care settings.

Products and Services
  • Endotoxin Activity Assay for rapid detection of gram-negative bacterial components
  • Polymyxin B-Hemoperfusion device for endotoxin removal from the bloodstream
  • Development of monoclonal and polyclonal antibodies for research and diagnostics
Growth Outlook
  • Expansion into international markets enhances revenue potential
  • Increasing demand for septic shock treatments drives product adoption
  • Ongoing research and development may lead to new product offerings
Financial Highlights
  • Recent quarterly revenue of CAD 893,301 shows potential for growth
  • Trailing twelve months (TTM) revenue reflects a significant increase compared to previous periods
  • Operating expenses remain high, indicating investment in future growth
Spectral Medical Inc. is positioned in a critical healthcare niche, focusing on septic shock treatment, which is a significant area of need in critical care. The company's innovative products, such as the Endotoxin Activity Assay and Polymyxin B-Hemoperfusion device, are designed to address urgent medical challenges. The growth outlook is promising, driven by expanding market opportunities and increasing demand for effective treatments. Recent financial data indicates a revenue increase, suggesting that the company is on a path toward improved performance. However, high operating expenses highlight the ongoing investment in research and development, which is essential for long-term success. Overall, Spectral Medical Inc. presents a compelling opportunity for investors interested in the healthcare sector, particularly in innovative solutions for critical care.
AI Generated • Jul 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Chris Seto, MBA

Website

www.spectraldx.com

Headquarters

Toronto, ON M9C 1C2, CA

EDTXF Financials

Key Financial Metrics (TTM)

Gross Margin

-79.25%

Operating Margin

-412.28%

Net Income Margin

-1377.18%

Return on Equity

61.00%

Return on Capital

N/A

Return on Assets

-830.76%

Earnings Yield

-9.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$290.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

293.55M

Volume

2.20K

Avg. Volume

8.60K

Financials (TTM)

Gross Profit

-CA$2.19M

Operating Income

-CA$11.39M

EBITDA

-CA$35.22M

Operating Cash Flow

-CA$11.12M

Capital Expenditure

-CA$28.00K

Free Cash Flow

-CA$11.15M

Cash & ST Invst.

CA$1.92M

Total Debt

CA$22.33M

Spectral Medical Performance Analysis

Spectral Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 1,280,482-19.6%
20232023-12-31CAD 1,183,978-7.5%
20242024-12-31CAD 1,668,66040.9%
20252025-12-31CAD 1,747,6704.7%
Spectral Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3042.1%
Q32025-09-30-17.0%
Q42025-12-31-43.5%
Q12026-03-31134.0%
Spectral Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.0315.5%
20232023-12-31CAD -0.0429.9%
20242024-12-31CAD -0.04-4.1%
20252025-12-31CAD -0.12197.0%
Spectral Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3084.7%
Q32025-09-30-1517.6%
Q42025-12-3191.2%
Q12026-03-31-3.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$893.30K

+56.2%

Gross Profit

-CA$2.05M

-557.8%

Gross Margin

-2.29%

N/A

Market Cap

$290.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.01M

N/A

Employees

29

N/A

Net Income

-CA$2.95M

+76.6%

EBITDA

-CA$3.33M

+70.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$1.92M

+15.1%

Total Debt

CA$22.33M

+46.1%

Accounts Receivable

CA$479.23K

+54.6%

Inventory

CA$479.23K

+138.4%

Long Term Debt

CA$4.72M

+1296.5%

Short Term Debt

CA$17.56M

+17.5%

Return on Assets

-8.31%

N/A

Return on Invested Capital

18.69%

N/A

Free Cash Flow

-CA$2.39M

-66.8%

Operating Cash Flow

-CA$2.39M

-66.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COGZFCogstate Limited
$1.75+0.00%
DMTRF3-D Matrix, Ltd.
$2.50+0.00%
CMVLFCellectis S.A.
$3.47+12.66%
ABTIAlterola Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About EDTXF

What is the current price of Spectral Medical?

Spectral Medical is trading at $0.99 per share.

What is the 52-week range for Spectral Medical?

Over the past 52 weeks, Spectral Medical has traded between $0.59 and $1.31.

How much debt does Spectral Medical have?

As of the most recent reporting period, Spectral Medical reported total debt of CA$15.96M.

How much cash does Spectral Medical have on hand?

Spectral Medical reported CA$1.37M in cash and cash equivalents in its most recent financial results.

What is Spectral Medical’s dividend yield?

Spectral Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services